Graduate School of Medicine, Chiba University Endocrine Metabolism/Hematology/Geriatric Medicine, Japan.
Graduate School of Medicine, Kanazawa University Cardiovascular Medicine, Japan.
Intern Med. 2024;63(15):2137-2142. doi: 10.2169/internalmedicine.2726-23. Epub 2024 Aug 1.
The patient was a 54-year-old woman with familial hypercholesterolemia and remarkable Achilles tendon thickening. At 20 years old, the patient had a total cholesterol level of approximately 300 mg/dL. She started receiving rosuvastatin (5 mg/day) for low-density lipoprotein cholesterol (LDL-C) 235 mg/dL at 42 years old, which was increased to 10 mg/day at 54 years old, decreasing her serum LDL-C level to approximately 90 mg/dL. The serum Lp (a) level was 9 mg/dL. A computed tomography coronary angiogram showed no significant stenosis. Next-generation sequencing revealed a frameshift variant in LDL receptor (LDLR) (heterozygous) and a missense variant in proprotein convertase subtilisin/kaxin type 9 (PCSK9) (heterozygous). Continued statin therapy, in addition to low Lp (a) and female sex, can help prevent cardiovascular disease.
患者为 54 岁女性,有家族性高胆固醇血症,跟腱显著增厚。20 岁时,患者的总胆固醇水平约为 300mg/dL。42 岁时,患者因低密度脂蛋白胆固醇(LDL-C)235mg/dL 开始接受瑞舒伐他汀(5mg/天)治疗,54 岁时增至 10mg/天,使血清 LDL-C 水平降至约 90mg/dL。血清脂蛋白(a)水平为 9mg/dL。计算机断层冠状动脉造影显示无明显狭窄。下一代测序显示 LDL 受体(LDLR)(杂合子)出现框移变异和前蛋白转化酶枯草溶菌素/ kexin 9 型(PCSK9)(杂合子)出现错义变异。持续他汀类药物治疗,加上低脂蛋白(a)和女性性别,有助于预防心血管疾病。